Interestingly, the ATXN2 gene has been found to be altered by copy number, mutation or expression in ~9% of breast cancers in the TCGA dataset (S6 Table) and this may be another mechanism for tumour cells to potentiate EGFR signalling. This evidence concerns the gene EGFR and breast cancer.